RICERCA E INNOVAZIONE QUALITA

1
RICERCA E INNOVAZIONEQUALITA E SVILUPPO
Presentazione di Umberto Bertazzoni Siena, 12
dicembre 2005
2
Priority 1, Life Sciences Primo Bando
Partner italiani valutati e selezionati (totali)
Appartenenza
3
Priority 1, Life Sciences Primo Bando
Partner italiani valutati e selezionati 1.2
Biotechnology
Partner valutati Partner selezionati
in lista di priorità
4
Priority 1, Life Sciences Secondo Bando
(totali) Appartenenza
Partner italiani valutati e selezionati

Partner valutati Partner selezionati
in lista di priorità
5
Priority 1, Life Sciences Primo Bando
Partner italiani valutati e selezionati 2.1
Major Diseases
Partner valutati Partner selezionati
in lista di priorità
6
Priority 1, Life Sciences Primo Bando
Partner italiani valutati e selezionati 2.3
Poverty Diseases
Partner valutati Partner selezionati
in lista di priorità
7
Quadro generale in negoziazione dei partecipanti
e finanziamenti per tipo di partecipante e per
paese nel primo bando della priorità 1
8
(No Transcript)
9
Priority 1, Life Sciences Secondo Bando
Partner italiani valutati e selezionati

1.2 Biotechnology
40
35
Partner valutati
Partner selezionati in lista di priorità
30
25
20
15
10
5
0
Pub-
Pri-
Pub-
SME
LE
Pub-
Pri-
Pub-
SME
LE
Pub-
Pri-
Pub-
SME
LE
Res-
Res-
Uni
Res-
Res-
Uni
Res-
Res-
Uni
Cnt
Cnt
Cnt
Cnt
Cnt
Cnt
IP
NoE
STREP
10
Priority 1, Life Sciences Secondo Bando
Partner italiani valutati e selezionati

2.1 Major Diseases
35
Partner valutati
Partner selezionati in lista di priorità
30
25
20
15
10
5
0
Pub-
Pri-
Pub-
SME
LE
Pub-
Pri-
Pub-
SME
LE
Pub-
Pri-
Pub-
SME
LE
Res-
Res-
Uni
Res-
Res-
Uni
Res-
Res-
Uni
Cnt
Cnt
Cnt
Cnt
Cnt
Cnt
IP
NoE
STREP
11
Appartenenza partecipanti italiani ai progetti in
negoziazione terzo bando
12
Italian participation in financed projects
(calls 1, 2 and 3 priority 1 fp6)

• in 223 projects (out of 417)
• 527 participants
• (some participants appear in more than one
  project)
• 9.4 of all participants (5611 in total)
• 43 different private companies
• (some appear in more than one project)

13
(No Transcript)
14
? Innovative Medicines
Joint Technology Initiative

• Long term objective
• To increase the competitiveness of the European
  Pharmaceutical industry, and to foster Europe as
  the most attractive place for pharmaceutical RD.
• Thereby enhancing access of innovative medicines
  to the benefit of patients and society.
• Aim
• To remove major bottlenecks in the drug
  development process, as identified by industry,
  and where research is the key.

15
Innovative Medicines Initiative

• Industry (under the leadership of EFPIA) has
  identified the bottlenecks in agreement with key
  stakeholders academia, regulatory agencies,
  patient organisations, clinical researchers,
  ethical experts, etc.
• A Strategic Research Agenda prioritising the
  research needs and how they should be implemented
  has been developed by panels of experts.

16
Innovative Medicines Initiative

• The Strategic Research Agenda will address
  bottlenecks in four main areas
• Improved prediction early indications of
  safety.
• Improved clinical performance early indications
  of efficacy by use of biomarkers.
• Better knowledge management through collaboration
  breaking information barriers at the
  interfaces.
• Bridging educational gaps pre-clinical and
  clinical research and breaking barriers between
  disciplines.